ArticleCell communication and signaling : CCS2025
Genetically platform presenting CD24 ScFv enhance antitumor immunity by restoring macrophage phagocytosis and modulating the immune environment.
Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and Safety of Olaparib Combined With Cediranib in the Treatment of Ovarian Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Technology in cancer research & treatmentPooled it
- Mesenchymal stromal cells regulate M2 macrophage polarization that promotes proliferation, migration, and invasion of renal cell carcinoma cells.Medical oncology (Northwood, London, England) · 2026Article
- Factors influencing the incidence of postoperative lymphedema in patients with locally advanced triple-negative breast cancer.World journal of surgical oncology · 2026Article
- Cervical cancer derived extracellular vesicles expressed higher level of CD24 and suppressed the phagocytosis of macrophages.Discover oncology · 2026Article
- The role of small extracellular vesicles in ovarian cancer drug resistance: from bench clues to clinical implications.Journal of ovarian research · 2026Review
- CD24 as an innate immune checkpoint in solid tumors: biology, biomarker stratification, and therapeutic translation.Frontiers in immunology · 2026Review
- Nocardia rubra cell wall skeleton-induced MARCO expression: implications for improved phagocytosis and cytokine secretion in tumor-associated macrophages.Frontiers in immunology · 2026Article
- Value Analysis of MRI Habitat Analysis Combined Model in the Diagnosis of Ovarian Tumors.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Immunotherapy has achieved remarkable progress in treating cancers that evade immune surveillance. Among the components of the tumor microenvironment, macrophages play important roles in maintaining homeostasis, preventing pathogen invasion, engulfing and promoting the adaptive immune response. It is acknowledged that blocking the CD24-Siglec-10 interaction significantly enhances the macrophage phagocytosis ability. In this study, we identified CD24 as an over-expressed molecule in ovarian and breast cancer using data from the GEO database and clinical samples. We then developed genetically programmable extracellular vesicles displaying CD24 single-chain variable fragment (CD24 scFv-EVs) and evaluated their ability to restore macrophage phagocytic activity and eliminate CD24-overexpressing cancer cells. Our findings demonstrate that CD24 scFv-EVs effectively block CD24 on ovarian cancer cells as well as breast cancer cells, thereby inhibiting the CD24-Siglec-10 pathway and enhancing macrophage-mediated clearance of cancer cells. Furthermore, CD24 scFv-EVs promote the polarization of tumor-infiltrated macrophages toward an M1-like phenotype. These results highlight CD24 blockade as a novel therapeutic strategy to target ovarian and breast cancer cells and enhance macrophage-driven tumor cell clearance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.